Related Experiment Videos
Mutagenicity tests on propiverine hydrochloride.
1Drug Safety Laboratory, Taiho Pharmaceutical Co., Ltd. Tokusima, Japan.
The Journal of Toxicological Sciences
|May 1, 1989
Summary
Propiverine hydrochloride (P-4) was evaluated for mutagenicity using bacterial reverse mutation and chromosomal aberration tests. Results indicate that P-4 exhibits no mutagenic activity in these assays.
Area of Science:
- Toxicology
- Genetics
Background:
- Propiverine hydrochloride (P-4) is a pharmaceutical compound requiring rigorous safety assessment.
- Evaluating the mutagenic potential is crucial for understanding drug safety profiles.
Purpose of the Study:
- To assess the mutagenic activity of propiverine hydrochloride (P-4).
- To determine if P-4 induces genetic mutations or chromosomal damage.
Main Methods:
- Bacterial reverse mutation assay (Ames test) using Salmonella typhimurium and Escherichia coli strains.
- In vitro chromosomal aberration test on Chinese hamster lung (CHL) cells.
- Tests were conducted with and without metabolic activation (S9 Mix).
Main Results:
- No significant increase in revertant colonies was observed in the Ames test across all strains, with or without S9 Mix.
- No significant incidence of structural or numerical chromosomal aberrations was found in CHL cells, with or without S9 Mix.
- Propiverine hydrochloride (P-4) demonstrated no mutagenic effects in either assay.
Conclusions:
- Propiverine hydrochloride (P-4) is not mutagenic based on the conducted in vitro assays.
- The findings support the safety profile of propiverine hydrochloride regarding genotoxicity.